文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早产儿视网膜病变玻璃体腔注射抗VEGF治疗的实践模式与结局:一项国际多中心研究

Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity: An International Multicenter Study.
PubMed 文献 · Ophthalmology · 2022-07-19

该国际多中心回顾性连续系列研究纳入2007至2021年接受抗VEGF注射治疗的早产儿视网膜病变(ROP)患儿共1677只眼(918例),报告注射实践模式、再治疗及并发症情况。总体再治疗率为36%,并发症发生在15只眼(0.9%),无眼内炎报告。美国患儿出生体重和胎龄更低,再注射联合激光再治疗更常见,但两地并发症发生率无差异。

要点

  • 共纳入1677只眼(918例),平均胎龄25.7周,平均出生体重787克。
  • 604只眼(36%)需要再治疗,其中79.8%仅用激光,10.6%仅再注射抗VEGF,9.6%联合激光与注射。
  • 并发症发生于15只眼(0.9%),无眼内炎报告。

核心结论

  • 抗VEGF注射治疗ROP安全且耐受良好,尽管实践模式存在差异。
  • 美国接受注射的ROP婴儿 tended to be younger and smaller,且治疗更早、再治疗更多。

研究设计与样本

  • 研究对象为2007年至2021年接受抗VEGF注射治疗的ROP患者,共1677只眼(918例)。

主要发现

  • 总体最常用30G针头(51%),注射象限最常见为颞下(51.3%)。
  • 距角膜缘距离范围为0.75至2毫米,最常见为1毫米(65%)。
  • 贝伐单抗是最常用抗VEGF药物(71.4%),64%的病例剂量为0.625毫克。
  • 美国患者出生体重和胎龄分别为665.6克和24.5周,低于非美国患者的912.7克和26.9周(P < 0.0001)。
  • 再注射联合激光再治疗在美国组比非美国组更常见(8.5% vs. 4.7% [P = 0.0016] 和 55% vs. 7.2% [P < 0.001])。

临床怎么用

  • 原文结论为抗VEGF注射治疗ROP安全且耐受良好,并指出美国患儿更年轻、更小且再治疗更多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report practice patterns of intravitreal injections of anti-VEGF for retinopathy of prematurity (ROP) and outcomes data with a focus on retreatments and complications. DESIGN: Multicenter, international, retrospective, consecutive series. SUBJECTS: Patients with ROP treated with anti-VEGF injections from 2007 to 2021. METHODS: Twenfty-three sites (16 United States [US] and 7 non-US) participated. Data collected included demographics, birth characteristics, examination findings, and methods of injections. Comparisons between US and non-US sites were made. MAIN OUTCOME MEASURES: Primary outcomes included number and types of retreatments as well as complications. Secondary outcomes included specifics of the injection protocols, including types of medication, doses, distance from limbus, use of antibiotics, and quadrants where injections were delivered. RESULTS: A total of 1677 eyes of 918 patients (43% female, 57% male) were included. Mean gestational age was 25.7 weeks (range, 21.2-41.5 weeks), and mean birth weight was 787 g (range, 300-2700 g). Overall, a 30-gauge needle was most commonly used (51%), and the quadrant injected was most frequently the inferior-temporal (51.3%). The distance from the limbus ranged from 0.75 to 2 mm, with 1 mm being the most common (65%). Bevacizumab was the most common anti-VEGF (71.4%), with a dose of 0.625 mg in 64% of cases. Overall, 604 (36%) eyes required retreatment. Of those, 79.8% were retreated with laser alone, 10.6% with anti-VEGF injection alone, and 9.6% with combined laser and injection. Complications after anti-VEGF injections occurred in 15 (0.9%) eyes, and no cases of endophthalmitis were reported. Patients in the United States had lower birth weights and gestational ages (665.6 g and 24.5 weeks, respectively) compared with non-US patients (912.7 g and 26.9 weeks, respectively) (P < 0.0001). Retreatment with reinjection and laser was significantly more common in the US compared with the non-US group (8.5% vs. 4.7% [P = 0.0016] and 55% vs. 7.2% [P < 0.001], respectively). There was no difference in the incidence of complications between the 2 geographic subgroups. CONCLUSIONS: Anti-VEGF injections for ROP were safe and well tolerated despite a variance in practice patterns. Infants with ROP receiving injections in the US tended to be younger and smaller, and they were treated earlier with more retreatments than non-US neonates with ROP.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Patel NA, Acaba-Berrocal LA, Hoyek S, et al. Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity: An International Multicenter Study. Ophthalmology. 2022. PMID: 35863512. doi:10.1016/j.ophtha.2022.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。